Novel mRNA Signature for Anti-TNF-α Therapy Primary Response in Patients With Ulcerative Colitis

Area of Science:

• Gastroenterology
• Immunology
• Genomics

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
• Anti-tumor necrosis factor α (anti-TNF-α) agents are common UC treatments.
• Only about two-thirds of UC patients initially respond to anti-TNF-α therapy.

Purpose of the Study:

• To develop a predictive tool for anti-TNF-α therapy response in UC patients.
• To identify gene expression patterns associated with treatment response.
• To explore the relationship between a predictive score and clinical features.

Main Methods:

• Integrated gene expression data from 79 UC patients.
• Calculated differentially expressed genes between responders and non-responders.
• Developed a response-associated transcription signature score (logOR_Score).

Main Results:

• Identified 2522 responsive and 1824 nonresponsive genes.
• Responsive genes linked to metabolism; nonresponsive genes to immune response.
• The logOR_Score accurately predicted anti-TNF-α efficacy and correlated with UC activity.

Conclusions:

• A novel transcription signature may personalize UC treatment.
• The logOR_Score provides insights into UC pathogenesis.
• Associations with clinical features and immune microenvironment warrant further study.